MX340094B - Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento. - Google Patents

Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento.

Info

Publication number
MX340094B
MX340094B MX2013004960A MX2013004960A MX340094B MX 340094 B MX340094 B MX 340094B MX 2013004960 A MX2013004960 A MX 2013004960A MX 2013004960 A MX2013004960 A MX 2013004960A MX 340094 B MX340094 B MX 340094B
Authority
MX
Mexico
Prior art keywords
complement
complement activation
individual
point
lateral flow
Prior art date
Application number
MX2013004960A
Other languages
English (en)
Spanish (es)
Other versions
MX2013004960A (es
Inventor
Olson Paul
Moss Don
Original Assignee
Kypha Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kypha Inc filed Critical Kypha Inc
Publication of MX2013004960A publication Critical patent/MX2013004960A/es
Publication of MX340094B publication Critical patent/MX340094B/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54386Analytical elements
    • G01N33/54387Immunochromatographic test strips
    • G01N33/54388Immunochromatographic test strips based on lateral flow
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4716Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases
    • G01N2800/125Adult respiratory distress syndrome
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/26Infectious diseases, e.g. generalised sepsis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7095Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
MX2013004960A 2010-11-02 2011-11-02 Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento. MX340094B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40929710P 2010-11-02 2010-11-02
PCT/US2011/058945 WO2012071145A1 (en) 2010-11-02 2011-11-02 Lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Publications (2)

Publication Number Publication Date
MX2013004960A MX2013004960A (es) 2013-12-16
MX340094B true MX340094B (es) 2016-06-27

Family

ID=46146161

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004960A MX340094B (es) 2010-11-02 2011-11-02 Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento.

Country Status (8)

Country Link
US (2) US9182396B2 (enExample)
EP (2) EP3095876A1 (enExample)
JP (1) JP5859557B2 (enExample)
AU (2) AU2011332241B2 (enExample)
CA (1) CA2816423A1 (enExample)
ES (1) ES2564290T3 (enExample)
MX (1) MX340094B (enExample)
WO (1) WO2012071145A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865164B2 (en) * 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
EP3095876A1 (en) 2010-11-02 2016-11-23 Kypha, Inc. Point of care lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders
US9110030B2 (en) 2012-06-29 2015-08-18 Daniel A. Kerschensteiner Colorimetric gelatinase assay
US9863944B2 (en) 2013-06-10 2018-01-09 Asahi Kasei Fibers Corporation Immunochromatographic diagnosis kit
ES2842283T3 (es) * 2014-05-02 2021-07-13 Uab Research Foundation Métodos y composiciones para el diagnóstico y tratamiento de la meningitis
US11029318B2 (en) * 2015-08-28 2021-06-08 Kypha, Inc. Methods for predicting and treating patients with increased risk of adverse pregnancy outcome
KR102141591B1 (ko) * 2016-05-13 2020-09-14 광주과학기술원 진단용 키트
WO2019190877A1 (en) * 2018-03-26 2019-10-03 Alexion Pharmaceuticals, Inc. High throughput method for measuring the protease activity of complement c3 convertase
EP3581934A1 (en) * 2018-06-14 2019-12-18 Otto-von-Guericke-Universität Magdeburg Complement factors for diagnosis of low-grade infections in a human subject
WO2021222169A1 (en) * 2020-04-27 2021-11-04 Zinselmeyer Bernd H Methods and systems for lateral flow immunoassay of various biological materials including sars-cov2
EP4217744A4 (en) * 2020-09-28 2024-11-06 Allegheny Singer Research Institute METHOD FOR DETERMINING A LEVEL OF A CELL FRAGMENT-BOUND COMPLEMENT ACTIVATION PRODUCT
EP4286850A4 (en) * 2021-01-26 2024-11-27 Sekisui Medical Co., Ltd. IMMUNOLOGICAL ASSAY PROCEDURE
EP4334719A4 (en) * 2021-05-07 2025-04-16 Kypha, Inc. TARGET MEASUREMENT
WO2023192436A1 (en) * 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212071A (en) * 1988-04-01 1993-05-18 The Johns Hopkins University Nucleic acids encoding a human C3b/C4b receptor (CR1)
JPS595958B2 (ja) 1975-12-30 1984-02-08 トウキヨウケイソウ カブシキガイシヤ 変量測定・伝送装置
EP0097440B1 (en) * 1982-06-14 1986-09-24 The Upjohn Company Method and kit for removing and assaying complement system fragments
SE452067B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Reagens for och sett vid immunkemisk bestemning av c3a
SE452065B (sv) 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
IL89790A (en) * 1988-04-01 2002-05-23 Johns Hopking University Nucleic acid sequences that encode and cells that produce cr1 protein and methods of production and purification
US7371582B2 (en) * 2002-01-23 2008-05-13 Boditechmed Inc. Lateral flow quantitative assay method and strip and laser-induced fluorescence detection device therefor
WO2004093636A2 (en) * 2003-04-17 2004-11-04 Rauno Joks PLASMA C5a LEVELS AS AN INDICATOR OF ASTHMA SEVERITY
KR20060015646A (ko) 2003-06-13 2006-02-17 유니버시티 오브 피츠버그 면역, 혈액 및 염증성 질환의 모니터링 방법
ATE421093T1 (de) 2003-09-29 2009-01-15 Peas Inst Ab Schnelle bestimmung verschiedener formen von hgf (heptocyte growth factor) in den körperflüssigkeiten
US20050255533A1 (en) * 2004-02-10 2005-11-17 Brendan Bioscience, Llc Comprehensive food allergy test
US20060292700A1 (en) * 2005-06-22 2006-12-28 Naishu Wang Diffused interrupted lateral flow immunoassay device and method
WO2006124888A2 (en) 2005-05-16 2006-11-23 Brendan Bioscience, Llc Detection of antigen specific immunocomplexes
US7910381B2 (en) 2005-10-13 2011-03-22 BioAssay Works Immuno gold lateral flow assay
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
JP2012503170A (ja) * 2008-07-15 2012-02-02 ラピッド パトゲン スクリーニング,インク. 側方流動イムノアッセイにおけるインサイツでの細胞の溶解
CA2750155A1 (en) * 2008-12-30 2010-07-08 Centocor Ortho Biotech Inc. Serum markers predicting clinical response to anti-tnf.alpha. antibodiesin patients with ankylosing spondylitis
US9291622B2 (en) * 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
US8865164B2 (en) 2010-11-02 2014-10-21 Kypha, Inc. Detecting complement activation
EP3095876A1 (en) 2010-11-02 2016-11-23 Kypha, Inc. Point of care lateral flow immunoassay for complement activation and methods of use for point-of-care assessment of complement-associated disorders

Also Published As

Publication number Publication date
EP2635702A1 (en) 2013-09-11
AU2016200772B2 (en) 2018-02-01
AU2011332241A1 (en) 2013-05-23
US20150346211A1 (en) 2015-12-03
AU2011332241B2 (en) 2015-11-26
AU2011332241A2 (en) 2013-06-13
WO2012071145A1 (en) 2012-05-31
ES2564290T3 (es) 2016-03-21
US9182396B2 (en) 2015-11-10
EP2635702B1 (en) 2016-02-03
MX2013004960A (es) 2013-12-16
AU2016200772A1 (en) 2016-02-25
JP5859557B2 (ja) 2016-02-10
CA2816423A1 (en) 2012-05-31
US20120141457A1 (en) 2012-06-07
EP2635702A4 (en) 2014-04-02
EP3095876A1 (en) 2016-11-23
JP2014502347A (ja) 2014-01-30
US9939446B2 (en) 2018-04-10

Similar Documents

Publication Publication Date Title
MX340094B (es) Inmunoensayo de flujo lateral para activacion de complemento y metodos de uso para valoracion en el punto de cuidado de trnstornos asociados con el complemento.
HK1220279A1 (zh) 预测对精神疾病治疗的应答的方法和系统
MX2016006252A (es) Tratamiento o prevencion de afecciones pulmonares con monoxido de carbono.
NZ608208A (en) Breast cancer diagnostics
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
WO2015102726A3 (en) A microfluidic device for real-time clinical monitoring and quantitative assessment of whole blood coagulation
WO2014028884A3 (en) Cancer diagnostics using biomarkers
PH12013502340A1 (en) Biomarkers for hedgehog inhibitor therapy
GB2484631A (en) System and methods for monitoring a well
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX2023002021A (es) Anticuerpos de union al componente de complemento 1 c1s para usarse en el tratamiento de trastornos autoinmune y aloinmune.
HK1208256A1 (en) Microfluidic pump
MY190476A (en) Steady state fluid flow verification for sample takeoff
IN2014KN02809A (enExample)
GB2544922A (en) Methods and systems for simulating a hydrocarbon field using a multi-point well connection method
GB201113992D0 (en) Device
WO2012068040A3 (en) Detection of vestibular disorders based on vestibular noise
GB2538374A (en) Determining formation gas composition during well drilling
EA201791707A1 (ru) Переносное устройство для оперативного измерения концентрации сероводорода в выходящем газовом потоке
WO2014141293A3 (en) A method and system for estimation of blood anylates
EA201290828A1 (ru) Устройство и способ контроля частиц
WO2014126796A3 (en) Methods of diagnosing, treating and monitoring diabetic retinopathy
UA78641U (ru) Способ прогнозирования тяжести больных острым панкреатитом
EP4328324A3 (en) Methods of diagnosing epilepsy
MX2018016216A (es) Deteccion de analitos de flujo lateral.

Legal Events

Date Code Title Description
FG Grant or registration